Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings

Exelixis, Inc.'s (NASDAQ:EXEL) price-to-earnings (or "P/E") ratio of 19.6x might make it look like a sell right now compared to the market in the United States, where around half of the companies have P/E ratios below 16x and even P/E's below 9x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's as high as it is.

We've discovered 1 warning sign about Exelixis. View them for free.

Exelixis certainly has been doing a good job lately as it's been growing earnings more than most other companies. The P/E is probably high because investors think this strong earnings performance will continue. If not, then existing shareholders might be a little nervous about the viability of the share price.

View our latest analysis for Exelixis

pe-multiple-vs-industry
NasdaqGS:EXEL Price to Earnings Ratio vs Industry April 16th 2025
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Exelixis.
Advertisement

How Is Exelixis' Growth Trending?

Exelixis' P/E ratio would be typical for a company that's expected to deliver solid growth, and importantly, perform better than the market.

If we review the last year of earnings growth, the company posted a terrific increase of 175%. The latest three year period has also seen an excellent 154% overall rise in EPS, aided by its short-term performance. So we can start by confirming that the company has done a great job of growing earnings over that time.

Shifting to the future, estimates from the analysts covering the company suggest earnings should grow by 22% per year over the next three years. That's shaping up to be materially higher than the 11% per year growth forecast for the broader market.

With this information, we can see why Exelixis is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.

The Final Word

While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.

As we suspected, our examination of Exelixis' analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.

It is also worth noting that we have found 1 warning sign for Exelixis that you need to take into consideration.

If these risks are making you reconsider your opinion on Exelixis, explore our interactive list of high quality stocks to get an idea of what else is out there.

Valuation is complex, but we're here to simplify it.

Discover if Exelixis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:EXEL

Exelixis

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0774.4% undervalued
214 users have followed this narrative
1 users have commented on this narrative
30 users have liked this narrative
SI
SimpleMan887
GME logo
SimpleMan887 on GameStop ·

GameStop will ace the financial crisis wave with its strategic Bitcoin investment and cash reserves

Fair Value:US$22089.4% undervalued
54 users have followed this narrative
2 users have commented on this narrative
21 users have liked this narrative
YI
HSAI logo
yiannisz on Hesai Group ·

The First Real Lidar Winner

Fair Value:US$27.0716.3% undervalued
14 users have followed this narrative
1 users have commented on this narrative
4 users have liked this narrative
TR
tripledub
TSM logo
tripledub on Taiwan Semiconductor Manufacturing ·

The Most Wonderful Monopoly in the Most Dangerous Neighbourhood on Earth

Fair Value:US$3812.7% undervalued
11 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

EV
SSE logo
evadav on SSE ·

Future Prosperity Awaits with SSE's Impressive 11% Revenue Growth

Fair Value:UK£31.7613.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CG
BLCO logo
CG86 on Bausch + Lomb ·

$BLCO & $COO The Silence BEFORE the AGM: A Retail Investor’s Timeline, Findings, and Opinion on SUSPICIOUS SILENCE!

Fair Value:US$39.2358.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AS
AstrisCorporateAdvisory
9556 logo
AstrisCorporateAdvisory on INTLOOP ·

Renewed focus on business investment

Fair Value:JP¥4.17k56.4% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TR
tripledub
MSFT logo
tripledub on Microsoft ·

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

Fair Value:US$3956.1% undervalued
44 users have followed this narrative
3 users have commented on this narrative
42 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$587.3136.9% undervalued
1350 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
RO
Robbo
TSLA logo
Robbo on Tesla ·

The academically fascinating Tesla

Fair Value:US$301.1k% overvalued
37 users have followed this narrative
11 users have commented on this narrative
31 users have liked this narrative